Thomas Harrington

Medicine & Life Sciences

1. Sickle Cell Anemia 100%
2. Antiphospholipid Syndrome 55%
3. Hydroxyurea 38%
4. Thrombotic Microangiopathies 36%
5. Deltaretrovirus 31%
6. Hexosaminidases 31%
7. Nivolumab 31%
8. Autoimmune Haemolytic Anaemia 30%
9. Adult T Cell Leukemia Lymphoma 29%
10. Albuminuria 26%
11. Intravenous Immunoglobulins 25%
12. Adenocarcinoma of Lung 24%
13. B-Cell Chronic Lymphocytic Leukemia 24%
14. Hemolysis 23%
15. Neuroimaging 20%
16. Risk Assessment 19%
17. Epidemiology 18%
18. Urine 16%
19. Autoantibodies 15%
20. Hemosiderin 13%
21. Kidney 11%
22. Lupus Coagulation Inhibitor 10%
23. Anemia 10%
24. Haemolytic Anaemia 10%
25. Hemorrhage 10%
26. Plasma Exchange 10%
27. Mortality 9%
28. Thrombosis 9%
29. Transplants 9%
30. Serologic Tests 9%
31. Life Expectancy 9%
32. Thrombocytopenia 8%
33. Creatinine 8%
34. Immunotherapy 8%
35. Respiratory Insufficiency 7%
36. Confidence Intervals 7%
37. Glucocorticoids 7%
38. Wounds and Injuries 6%
39. Drug Therapy 6%
40. Bone Marrow 6%
41. Biomarkers 6%
42. Albumins 6%
43. Fibrin Fibrinogen Degradation Products 6%
44. Lung 6%
45. Fetal Hemoglobin 6%
46. beta 2-Glycoprotein I 6%
47. Menorrhagia 5%
48. Nuclear Antigens 5%
49. Tricuspid Valve Insufficiency 5%
50. Wechsler Scales 5%